AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
BA   180.08 (+0.67%)
AAPL   381.37 (+2.33%)
MSFT   212.83 (+2.20%)
FB   243.58 (+1.13%)
GOOGL   1,503.60 (+0.92%)
AMZN   3,081.11 (+2.70%)
CGC   16.33 (-1.03%)
BABA   257.68 (+8.95%)
MU   49.71 (+1.26%)
TSLA   1,365.88 (-1.73%)
AMD   53.43 (+0.94%)
ACB   12.16 (-2.09%)
F   6.09 (-0.49%)
GILD   75.61 (-1.06%)
DIS   116.66 (+2.67%)
BAC   23.10 (+0.39%)
BA   180.08 (+0.67%)
Log in

NYSEAMERICAN:OGENOragenics Stock Price, Forecast & News

$0.79
+0.02 (+2.65 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.75
Now: $0.79
$0.84
50-Day Range N/A
52-Week Range
$0.35
Now: $0.79
$0.92
Volume4.93 million shs
Average Volume2.42 million shs
Market Capitalization$43.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oragenics, Inc. develops novel antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring chemical agent for use in weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013; a license agreement with LPThera LLC to develop LPT3-04; and a license agreement Texas A&M University System for access to new homologs of the lantibiotic MU1140 and other lantibiotics. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.12 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OGEN
CUSIPN/A
Phone+1-813-2867900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6
Market Cap$43.60 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive OGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.

Oragenics (NYSEAMERICAN:OGEN) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Oragenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oragenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Oragenics.

When is Oragenics' next earnings date?

Oragenics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Oragenics.

How were Oragenics' earnings last quarter?

Oragenics Inc (NYSEAMERICAN:OGEN) issued its earnings results on Friday, May, 15th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.03. View Oragenics' earnings history.

When did Oragenics' stock split? How did Oragenics' stock split work?

Shares of Oragenics reverse split on Monday, January 22nd 2018. The 1-10 reverse split was announced on Monday, January 8th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 19th 2018. An investor that had 100 shares of Oragenics stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for OGEN?

1 analysts have issued 1-year price objectives for Oragenics' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Oragenics' share price to reach $2.00 in the next year. This suggests a possible upside of 153.2% from the stock's current price. View analysts' price targets for Oragenics.

Has Oragenics been receiving favorable news coverage?

News coverage about OGEN stock has trended negative on Wednesday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oragenics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Oragenics.

Are investors shorting Oragenics?

Oragenics saw a drop in short interest in June. As of June 30th, there was short interest totaling 858,300 shares, a drop of 12.0% from the June 15th total of 974,800 shares. Based on an average daily trading volume, of 2,710,000 shares, the short-interest ratio is presently 0.3 days. Currently, 2.2% of the shares of the stock are short sold. View Oragenics' Current Options Chain.

Who are some of Oragenics' key competitors?

What other stocks do shareholders of Oragenics own?

Who are Oragenics' key executives?

Oragenics' management team includes the following people:
  • Dr. Alan F. Joslyn, Pres, CEO & Director (Age 60)
  • Mr. Michael O. Sullivan CPA, CFO, Sec. & Treasurer (Age 63)
  • Dr. Martin Handfield, Sr. VP of Discovery Research (Age 48)
  • Dr. Raman Bedi, Chairman of International Scientific Advisory Board and Sr. Consultant

What is Oragenics' stock symbol?

Oragenics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OGEN."

How do I buy shares of Oragenics?

Shares of OGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oragenics' stock price today?

One share of OGEN stock can currently be purchased for approximately $0.79.

How big of a company is Oragenics?

Oragenics has a market capitalization of $43.74 million. Oragenics employs 6 workers across the globe.

What is Oragenics' official website?

The official website for Oragenics is www.oragenics.com.

How can I contact Oragenics?

Oragenics' mailing address is 4902 Eisenhower Blvd Ste 125, TAMPA, FL 33634-6342, United States. The biotechnology company can be reached via phone at +1-813-2867900.

This page was last updated on 7/8/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.